ERBB2 and breast carcinoma: These models may be clinically useful and could provide an orthogonal approach for calling key features like ER, PR, and HER2 status in breast cancer, especially in equivocal cases, given the growing use of DNA exomes and somatic mutation gene panels in the cancer clinic.